share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K:重大事件
美股SEC公告 ·  2024/10/04 20:04

Moomoo AI 已提取核心信息

Allarity Therapeutics announced the appointment of Jeremy R. Graff, Ph.D., as President and Chief Development Officer effective September 30, 2024. Dr. Graff brings over 25 years of biotech/pharma industry experience, including a 17-year tenure at Eli Lilly where he led the translational oncology group advancing 31 clinical assets. He will oversee the company's clinical development programs, particularly the advancement of stenoparib, a dual PARP and Tankyrase inhibitor.The company has also strengthened its leadership team with two key appointments: Jose Iglesias, M.D., joins as Consultant Chief Medical Officer, bringing 35 years of global pharmaceutical experience including roles at Celgene and Eli Lilly; and Jesper Høiland, former President of Novo Nordisk's U.S. operations, joins as Strategic Advisor.Under his employment agreement, Dr. Graff will receive an annual base salary of $475,000, RSUs valued at $250,000, up to 45% annual bonus opportunity, and a $75,000 signing bonus. The agreement includes severance provisions of nine months' salary for termination without cause, extending to twelve months in case of change-of-control.
Allarity Therapeutics announced the appointment of Jeremy R. Graff, Ph.D., as President and Chief Development Officer effective September 30, 2024. Dr. Graff brings over 25 years of biotech/pharma industry experience, including a 17-year tenure at Eli Lilly where he led the translational oncology group advancing 31 clinical assets. He will oversee the company's clinical development programs, particularly the advancement of stenoparib, a dual PARP and Tankyrase inhibitor.The company has also strengthened its leadership team with two key appointments: Jose Iglesias, M.D., joins as Consultant Chief Medical Officer, bringing 35 years of global pharmaceutical experience including roles at Celgene and Eli Lilly; and Jesper Høiland, former President of Novo Nordisk's U.S. operations, joins as Strategic Advisor.Under his employment agreement, Dr. Graff will receive an annual base salary of $475,000, RSUs valued at $250,000, up to 45% annual bonus opportunity, and a $75,000 signing bonus. The agreement includes severance provisions of nine months' salary for termination without cause, extending to twelve months in case of change-of-control.
Allarity Therapeutics宣布任命Jeremy R. Graff博士为总裁兼首席开发官,任命自2024年9月30日起生效。Graff博士拥有超过25年的生物技术/药品行业经验,其中在礼来公司工作了17年,领导了转化肿瘤学团队,推进了31项临床资产。他将负责公司的临床开发计划,特别是促进斯特诺帕利(stenoparib)这一双重PARP和Tankyrase抑制剂的发展。该公司还通过两项重要任命加强了领导团队:Jose Iglesias万博士担任顾问首席医疗官,拥有35年的全球药品经验,包括在Celgene和礼来公司的任职;以及前诺和诺德美国业务总裁Jesper Høiland作为...展开全部
Allarity Therapeutics宣布任命Jeremy R. Graff博士为总裁兼首席开发官,任命自2024年9月30日起生效。Graff博士拥有超过25年的生物技术/药品行业经验,其中在礼来公司工作了17年,领导了转化肿瘤学团队,推进了31项临床资产。他将负责公司的临床开发计划,特别是促进斯特诺帕利(stenoparib)这一双重PARP和Tankyrase抑制剂的发展。该公司还通过两项重要任命加强了领导团队:Jose Iglesias万博士担任顾问首席医疗官,拥有35年的全球药品经验,包括在Celgene和礼来公司的任职;以及前诺和诺德美国业务总裁Jesper Høiland作为战略顾问加入。根据他的雇佣协议,Graff博士将获得475,000美元的年基本薪资,价值250,000美元的限制性股票单位(RSUs),最高可达45%的年奖金机会,以及75,000美元的签约奖金。该协议包括在无故解雇情况下的九个月薪水的遣散条款,在控制权变更的情况下延长至十二个月。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息